December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

262.56 USD -2.59 (-0.98%)
Streaming Delayed Price Updated: 7:36 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
New Research Coverage Highlights Texas Instruments, Biogen, Sanchez Energy, Amazon, Sirius XM, and JPMorgan Chase — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Texas Instruments... 
From GlobeNewswire News Releases
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
From ACN Newswire
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
From ACN Newswire
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced... 
From GlobeNewswire News Releases
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced... 
From PR Newswire
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced... 
From GlobeNewswire News Releases
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced... 
From PR Newswire
Bill Gates Dedicates $30M into Alzheimer's Treatments
From ACCESSWIRE
AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,... 
From GlobeNewswire News Releases
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018. The live webcast will... 
From GlobeNewswire News Releases
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
Biogen (Nasdaq:BIIB) announced it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC) in Chicago (July... 
From GlobeNewswire News Releases
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
From ACN Newswire
Is it time to buy stock in Advanced Micro Devices, Alibaba, Biogen, Chesapeake Energy or Micron?
InvestorsObserver issues critical PriceWatch Alerts for AMD, BABA, BIIB, CHK, and MU. 
From PR Newswire
Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months
- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid... 
From PR Newswire
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ:BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced... 
From GlobeNewswire News Releases
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
Biogen (Nasdaq:BIIB) announced today it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics Co., Ltd and... 
From GlobeNewswire News Releases
Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018
Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2018 financial results on Tuesday, July 24, 2018, before the financial markets open. 
From GlobeNewswire News Releases
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018. The live webcast will be from 8:00-9:00... 
From GlobeNewswire News Releases
Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education
The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the development of local STEM (science, technology, engineering,... 
From GlobeNewswire News Releases
Sanofi, Genentech and Celgene Lead the Way in Reputation Institute’s 2018 US Pharma RepTrak®, The Largest Study on Reputation of Pharmaceutical Brands in the US
Findings reveal critical importance of ethical governance as prevailing disruption and erosion of trust cause major shake-up in pharma company reputations 
From GlobeNewswire News Releases
Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018
Samsung Bioepis Co., Ltd. and Biogen (Nasdaq:BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™... 
From Business Wire News Releases
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Biogen (Nasdaq:BIIB) today announced it will present data from its SPINRAZA clinical development program – the largest of its kind, with more than six years of data – for spinal muscular atrophy (SMA)... 
From GlobeNewswire News Releases
Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
Biogen (Nasdaq:BIIB) announced today it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4... 
From GlobeNewswire News Releases
Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it closed its expanded strategic collaboration with Biogen (Nasdaq: BIIB) to discover and develop novel antisense drugs for a broad range... 
From PR Newswire
Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months
RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN 
From PR Newswire
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
From ACN Newswire
Biogen Appoints Daniel Karp as EVP, Corporate Development
Biogen (Nasdaq:BIIB) announced today the appointment of Daniel Karp as Executive Vice President, Corporate Development effective June 11, 2018. 
From GlobeNewswire News Releases
Biogen Celebrates 40 Years as a Pioneer in Neuroscience
Biogen (Nasdaq:BIIB): 
From Business Wire News Releases
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab 
From Business Wire News Releases
Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism
From PR Newswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.